Vistin Pharma ASALTS:0RAM 77 Return-on-Tangible-Asset is 19.25% as of Mar. 2026, which is 104% above its 10-year median of 9.42. GuruFocus rates LTS:0RAM with a GF Score™ of 77/100 and a GF Value™ of kr25.61 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,005 Drug Manufacturers companies, Vistin Pharma ASA ranks better than 91.84% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Vistin Pharma ASA's annualizedNet Income for the quarter that ended in Mar. 2026 was kr86.0 Mil. Vistin Pharma ASA's average total tangible assets for the quarter that ended in Mar. 2026 was kr446.5 Mil. Therefore, Vistin Pharma ASA's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 19.25%.
The historical rank and industry rank for Vistin Pharma ASA's Return-on-Tangible-Asset or its related term are showing as below:
LTS:0RAM'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -23.47 Med: 9.42 Max: 27.54
Current: 17.33
During the past 13 years, Vistin Pharma ASA's highest Return-on-Tangible-Asset was 27.54%. The lowest was -23.47%. And the median was 9.42%.
LTS:0RAM's Return-on-Tangible-Asset is ranked better than 91.84% of 1005
companies
in the Drug Manufacturers industry
Industry Median: 3.16
vs LTS:0RAM: 17.33
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Vistin Pharma ASA Return-on-Tangible-Asset Related Terms
Vistin Pharma ASA Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Vistin Pharma ASA's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RAM vs ZTS, UTHR, VTRS: Return-on-Tangible-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vistin Pharma ASA's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vistin Pharma ASA Return-on-Tangible-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vistin Pharma ASA's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Vistin Pharma ASA's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 19.25% mean?
Vistin Pharma ASA (LTS:0RAM) has a Return-on-Tangible-Asset of 19.25% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vistin Pharma ASA and its competitors. This is 104% above median its historical median of 9.42. According to the industry distribution chart, Vistin Pharma ASA ranks #82 out of 1005 companies in the Drug Manufacturers industry, placing it in the top 8.2%.
Is Vistin Pharma ASA's Return-on-Tangible-Asset too high?
Vistin Pharma ASA's current Return-on-Tangible-Asset of 19.25% is 104% above median its 10-year median of 9.42. The Drug Manufacturers industry median Return-on-Tangible-Asset is 3.16. Vistin Pharma ASA's value of 19.25% is 509.2% above this industry median. Based on the distribution chart, Vistin Pharma ASA ranks #82 out of 1005 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Vistin Pharma ASA has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Vistin Pharma ASA's Return-on-Tangible-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vistin Pharma ASA ranks #82 out of 1005 companies for Return-on-Tangible-Asset. This places Vistin Pharma ASA in the top 8% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 3.16. Vistin Pharma ASA's value of 19.25% is 509.2% above this benchmark. While the company's 10-year median is 9.42 vs. the industry median of 3.16, Vistin Pharma ASA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Drug Manufacturers company?
The median Return-on-Tangible-Asset among Drug Manufacturers companies is 3.16, based on 1,005 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vistin Pharma ASA's current Return-on-Tangible-Asset of 19.25% is 509.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vistin Pharma ASA and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Asset is 3.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vistin Pharma ASA's current Return-on-Tangible-Asset is 19.25%, which is 104% above median its own 10-year median of 9.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vistin Pharma ASA stock overvalued right now?
Based on GuruFocus' analysis, Vistin Pharma ASA (LTS:0RAM) is currently considered Modestly Undervalued. The stock's GF Value™ is kr25.61, compared to a current price of kr20.70 — trading 19.2% below its estimated fair value. The current Return-on-Tangible-Asset is 19.25%, which is 104% above median its 10-year median of 9.42 and 509.2% above the Drug Manufacturers industry median of 3.16. Vistin Pharma ASA's overall GF Score™ is 77/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Vistin Pharma ASA (LTS:0RAM), the current Return-on-Tangible-Asset is 19.25% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vistin Pharma ASA (LTS:0RAM) Overvalued in 2026?
Based on GuruFocus' analysis, Vistin Pharma ASA stock appears to be undervalued.
The current stock price of kr20.70 is trading 19.2% below its estimated GF Value™ of kr25.61.
GuruFocus considers Vistin Pharma ASA to be Modestly Undervalued.
Key valuation signals for LTS:0RAM:
Return-on-Tangible-Asset: 19.25% (104% above median its 10-year median of 9.42)
GF Value™: kr25.61 vs. price of kr20.70 (19.2% below fair value)
Industry Position: 509.2% above the Drug Manufacturers median (#82 of 1005)
No single metric tells the full story. See the LTS:0RAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vistin Pharma ASA is a pharmaceutical company engaged in the production and supply of active pharmaceutical ingredients (APIs). The company operates in one business segment, Pharmaceuticals, and is a supplier of Metformin, which is used as a standard treatment for Type 2 diabetes. The company generates revenue across multiple geographic regions, including Africa, Europe, Asia, and North and South America.
77GF Score
Get the complete analysis for LTS:0RAM
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RAM has been successfully added to your 
